Albertson's trains almost 3,000 pharmacists to administer naloxone
Albertson’s Cos. have trained close to 3,000 pharmacists in administering naloxone to treat patients overdosing on opioids. Read More »
Genentech sees positive results for Phase II study combining Tecentriq
Genentech's Phase II Mmotion150 study for Tecentriq compared Tecentriq plus Avastin and Tecentriq monotherapy to sunitinib alone reinforced the potential of the combination drug for the treatment of patients with previously untreated, locally advanced or metastatic renal cell carcinoma. Read More »
Report on asthma management taps allergy immunotherapy as treatment
The Global Initiative for Asthma’s report, Global Strategy for Asthma Management and Prevention, is recommending allergy immunotherapy as a treatment option. Read More »
Tivantinib's Phase III study fails to meet primary endpoint
ArQule Inc. and Daiichi Sankyo's METIV-HCC Phase 3 study of tivantinib in hepatocellular carcinoma failed to meet its primary endpoint of improving overall survival. Read More »
Allergan to sponsor Alzheimer's Foundation of America's education tour
Allergan will sponsor the Alzheimer's Foundation of America's (AFA) "15th Anniversary National Educating America Tour” that honors AFA’s 15 years of Alzheimer’s education. Read More »
Allergan raises awareness of Chronic Dry Eye
Allergan recently announced a new campaign to raise awareness for Chronic Dry Eye, using the slogan “before we had our voice, we had eyes.” Read More »
Alerts Sign-up